SCHEMBL4122856

SCHEMBL4122856

O=C(O)Cc1ccc(NC2=NC(=O)C(=Cc3cccc(N4CCN(c5ccccn5)CC4)c3)S2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.42
ALDH1A1 P00352 5/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
HTT P42858 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
AOC3 Q16853 2/20 0.42
DUSP22 Q9NRW4 2/20 0.40
DCTPP1 Q9H773 1/20 0.39
DUSP3 P51452 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
BACE1 P56817 1/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 3/20 0.37
ATM Q13315 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122851 1.00 KDM4E (0.42) KDM4EALDH1A1CYP3A4CYP2C9HTT
SCHEMBL4134034 0.82 DUSP22 (0.48) KDM4EALDH1A1HTTDUSP22DUSP3
SCHEMBL4134037 0.82 DUSP22 (0.48) KDM4EALDH1A1HTTDUSP22DUSP3
SCHEMBL4138121 0.81 NSD2 (0.43) KDM4EALDH1A1HTTDUSP22DUSP3
SCHEMBL4138118 0.81 NSD2 (0.43) KDM4EALDH1A1HTTDUSP22DUSP3
SCHEMBL4121542 0.80 LMNA (0.43) KDM4EALDH1A1HTTDUSP22DUSP3
SCHEMBL4121541 0.80 LMNA (0.43) KDM4EALDH1A1HTTDUSP22DUSP3
SCHEMBL4133862 0.79 DUSP22 (0.49) ALDH1A1DUSP22DUSP3SMN1; SMN2
SCHEMBL4133860 0.79 DUSP22 (0.49) ALDH1A1DUSP22DUSP3SMN1; SMN2
SCHEMBL4128001 0.79 FGFR1 (0.45) ALDH1A1HTTDUSP22DUSP3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ KDM4E 1692/4885ALDH1A1 216/4885CYP3A4 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.